CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Fulvestrant

氟维司群 杂质对照品Fulvestrant Impurities

EP41 个杂质条目41 impurity entries

本页汇总 氟维司群 的 41 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 41 impurity reference standards of Fulvestrant with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 氟维司群(Fulvestrant)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesPFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability
    Cellular signalling · 2024 · Jia W et al.  ·  PMID 38640982  ·  DOI
  2. 分析方法Analytical MethodsStability Indicating HPLC Method for the Determination of Fulvestrant in Pharmaceutical Formulation in Comparison with Linear Sweep Voltammetric Method
    Iranian journal of pharmaceutical research : IJPR · 2016 · Atila A et al.  ·  PMID 27980572
  3. 分析方法Analytical MethodsDevelopment and validation of reversed-phase-HPLC method for simultaneous quantification of fulvestrant and disulfiram in liposomes
    Bioanalysis · 2023 · Nsairat H et al.  ·  PMID 37847056  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
    Pharmaceuticals (Basel, Switzerland) · 2022 · Turković L et al.  ·  PMID 35631440  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisVisible-Light-Mediated Iodoperfluoroalkylation of Alkenes in Flow and Its Application to the Synthesis of a Key Fulvestrant Intermediate
    Organic letters · 2019 · Rosso C et al.  ·  PMID 31247766  ·  DOI

氟维司群 —— 原料药与杂质对照品Fulvestrant — drug substance & impurities

共 41 个条目(含原料药本体)41 items incl. the drug substance
Fulvestrant Impurity 1 (Fulvestrant EP Impurity A) (Fulvestrant β-Isomer ) structure
EPA
氟维司群杂质1 (氟维司群EP杂质A) (氟维司群β-异构体)Fulvestrant Impurity 1 (Fulvestrant EP Impurity A) (Fulvestrant β-Isomer )
Fulvestrant Impurity 1 (Fulvestrant EP Impurity A) (Fulvestrant β-Isomer )
CAS No.407577-53-1
Chemical FormulaC32H47F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 2 (Fulvestrant EP Impurity B) (Fulvestrant Sulfone) structure
EPB
氟维司群杂质2 (氟维司群EP杂质B) (氟维司群砜)Fulvestrant Impurity 2 (Fulvestrant EP Impurity B) (Fulvestrant Sulfone)
Fulvestrant Impurity 2 (Fulvestrant EP Impurity B) (Fulvestrant Sulfone)
CAS No.98008-06-1
Chemical FormulaC32H47F5O4S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 3 (Fulvestrant EP Impurity C) (Fulvestrant Extended ) structure
EPC
氟维司群杂质3 (氟维司群EP杂质C) (氟维司群延长)Fulvestrant Impurity 3 (Fulvestrant EP Impurity C) (Fulvestrant Extended )
Fulvestrant Impurity 3 (Fulvestrant EP Impurity C) (Fulvestrant Extended )
CAS No.2482852-42-4
Chemical FormulaC41H65F5O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 4 (Fulvestrant EP Impurity D) (Fulvestrant Sterol Dimer) structure
EPD
氟维司群杂质4 (氟维司群EP杂质D)(氟维司群甾醇二聚体)Fulvestrant Impurity 4 (Fulvestrant EP Impurity D) (Fulvestrant Sterol Dimer)
Fulvestrant Impurity 4 (Fulvestrant EP Impurity D) (Fulvestrant Sterol Dimer)
CAS No.2483797-59-5
Chemical FormulaC45H64O4
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 5 (Fulvestrant EP Impurity E) (Δ6,7-Fulvestrant) structure
EPE
氟维司群杂质5 (氟维司群EP杂质E) (Δ6,7-氟维司群)Fulvestrant Impurity 5 (Fulvestrant EP Impurity E) (Δ6,7-Fulvestrant)
Fulvestrant Impurity 5 (Fulvestrant EP Impurity E) (Δ6,7-Fulvestrant)
CAS No.2170200-14-1
Chemical FormulaC32H45F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 8 structure
8
氟维司群杂质8Fulvestrant Impurity 8
Fulvestrant Impurity 8
CAS No.2490287-87-9
Chemical FormulaC29H43BrO3
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 22 structure
22
氟维司群杂质22Fulvestrant Impurity 22
Fulvestrant Impurity 22
CAS No.111160-50-0
Chemical FormulaC5H5F5O
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 26 structure
26
氟维司群杂质26Fulvestrant Impurity 26
Fulvestrant Impurity 26
CAS No.7291-41-0
Chemical FormulaC18H22O2
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 28 structure
28
氟维司群杂质28Fulvestrant Impurity 28
Fulvestrant Impurity 28
CAS No.148757-89-5
Chemical FormulaC14H24BrF5S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 29 structure
29
氟维司群杂质29Fulvestrant Impurity 29
Fulvestrant Impurity 29
CAS No.148757-88-4
Chemical FormulaC5H7F5S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 31 structure
31
氟维司群杂质31Fulvestrant Impurity 31
Fulvestrant Impurity 31
CAS No.148043-73-6
Chemical FormulaC5H7F5O
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 39 structure
39
氟维司群杂质39Fulvestrant Impurity 39
Fulvestrant Impurity 39
CAS No.875573-60-7
Chemical FormulaC35H60O4Si
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 42 structure
42
氟维司群杂质42Fulvestrant Impurity 42
Fulvestrant Impurity 42
CAS No.66-27-3
Chemical FormulaC2H6O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 43 structure
43
氟维司群杂质43Fulvestrant Impurity 43
Fulvestrant Impurity 43
CAS No.875573-67-4
Chemical FormulaC27H41BrO2
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 47 structure
47
氟维司群杂质47Fulvestrant Impurity 47
Fulvestrant Impurity 47
CAS No.403656-89-3
Chemical FormulaC32H45F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 48 structure
48
氟维司群杂质48Fulvestrant Impurity 48
Fulvestrant Impurity 48
CAS No.2858589-78-1
Chemical FormulaC32H45F5O4S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 49 structure
49
氟维司群杂质49Fulvestrant Impurity 49
Fulvestrant Impurity 49
CAS No.1912-30-7
Chemical FormulaC4H10O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 50 structure
50
氟维司群杂质50Fulvestrant Impurity 50
Fulvestrant Impurity 50
CAS No.1912-28-3
Chemical FormulaC3H8O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 51 structure
51
氟维司群杂质51Fulvestrant Impurity 51
Fulvestrant Impurity 51
CAS No.90971-86-1
Chemical FormulaC6H14O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 52 structure
52
氟维司群杂质52Fulvestrant Impurity 52
Fulvestrant Impurity 52
CAS No.14245-63-7
Chemical FormulaC6H14O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 53 structure
53
氟维司群杂质53Fulvestrant Impurity 53
Fulvestrant Impurity 53
CAS No.80817-90-9
Chemical FormulaC8H18O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 54 structure
54
氟维司群杂质54Fulvestrant Impurity 54
Fulvestrant Impurity 54
CAS No.200881-89-6
Chemical FormulaC6H11NO3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 55 structure
55
氟维司群杂质55Fulvestrant Impurity 55
Fulvestrant Impurity 55
CAS No.2170200-16-3
Chemical FormulaC32H45F5O2S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 58 structure
58
氟维司群杂质58Fulvestrant Impurity 58
Fulvestrant Impurity 58
CAS No.27607-77-8
Chemical FormulaC4H9F3O3SSi
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 60 structure
60
氟维司群杂质60Fulvestrant Impurity 60
Fulvestrant Impurity 60
CAS No.252947-01-6
Chemical FormulaC6H9F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 63 structure
63
氟维司群杂质63Fulvestrant Impurity 63
Fulvestrant Impurity 63
CAS No.415927-29-6
Chemical FormulaC34H51F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 64 structure
64
氟维司群杂质64Fulvestrant Impurity 64
Fulvestrant Impurity 64
CAS No.153004-31-0
Chemical FormulaC32H47F5O2S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 65 structure
65
氟维司群杂质65Fulvestrant Impurity 65
Fulvestrant Impurity 65
CAS No.403656-84-8
Chemical FormulaC47H65F5O13S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 66 structure
66
氟维司群杂质66Fulvestrant Impurity 66
Fulvestrant Impurity 66
CAS No.261506-24-5
Chemical FormulaC34H49F5O4S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 67 structure
67
氟维司群杂质67Fulvestrant Impurity 67
Fulvestrant Impurity 67
CAS No.1221256-46-7
Chemical FormulaC33H49F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 68 structure
68
氟维司群杂质68Fulvestrant Impurity 68
Fulvestrant Impurity 68
CAS No.1107606-70-1
Chemical FormulaC32H45F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 69 structure
69
氟维司群杂质69Fulvestrant Impurity 69
Fulvestrant Impurity 69
CAS No.862700-70-7
Chemical FormulaC42H61F5O5S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 70 structure
70
氟维司群杂质70Fulvestrant Impurity 70
Fulvestrant Impurity 70
CAS No.261506-28-9
Chemical FormulaC38H55F5O9S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 71 structure
71
氟维司群杂质71Fulvestrant Impurity 71
Fulvestrant Impurity 71
CAS No.261506-27-8
Chemical FormulaC38H55F5O9S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 83 structure
83
氟维司群杂质83Fulvestrant Impurity 83
Fulvestrant Impurity 83
CAS No.875573-69-6
Chemical FormulaC34H49F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 84 structure
84
氟维司群杂质84Fulvestrant Impurity 84
Fulvestrant Impurity 84
CAS No.1673530-94-3
Chemical FormulaC59H87F5O4S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 85 structure
85
氟维司群杂质85Fulvestrant Impurity 85
Fulvestrant Impurity 85
CAS No.2490287-71-1
Chemical FormulaC27H41ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 90 structure
90
氟维司群杂质90Fulvestrant Impurity 90
Fulvestrant Impurity 90
CAS No.94099-52-2
Chemical FormulaC6H9F5O
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 92 structure
92
氟维司群杂质92Fulvestrant Impurity 92
Fulvestrant Impurity 92
CAS No.374-27-6
Chemical FormulaC4H3F5
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 97 structure
97
氟维司群杂质97Fulvestrant Impurity 97
Fulvestrant Impurity 97
CAS No.1807900-80-6
Chemical FormulaC32H47F5O3S
Purity>95%询价On request
10mg25mg50mg100mg
Fulvestrant Impurity 98 structure
98
氟维司群杂质98Fulvestrant Impurity 98
Fulvestrant Impurity 98
CAS No.1316849-17-8
Chemical FormulaC32H47F5O3S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

氟维司群 —— 研究文献与合成路线Fulvestrant — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 氟维司群 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Fulvestrant. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
    Hamilton EP, Ma C, De Laurentiis M, et al. · Future oncology (London, England) · 2024 · 被引 97cited 97
  2. The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
    Finnegan RM, Elshazly AM, Patel NH, et al. · Frontiers in oncology · 2022 · 被引 20cited 20
  3. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
    Nardone A, Weir H, Delpuech O, et al. · British journal of cancer · 2019 · 被引 51cited 51
  4. Stability Indicating HPLC Method for the Determination of Fulvestrant in Pharmaceutical Formulation in Comparison with Linear Sweep Voltammetric Method
    Atila A, Yilmaz B, Kadioglu Y · Iranian journal of pharmaceutical research : IJPR · 2016
  5. The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor
    Casa AJ, Hochbaum D, Sreekumar S, et al. · Molecular and cellular endocrinology · 2015 · 被引 21cited 21
  6. The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer
    Jaiswal SK, Fedkenheuer K, Khamar R, et al. · Cancer letters · 2025 · 被引 6cited 6

合成与制备工艺专利Synthesis & process patents

  1. PROCESSES AND INTERMEDIATES FOR THE PRODUCTION OF FULVESTRANT
    ETTEMA GERRIT JAN BOUKE, GIELING REINERUS GERARDUS · 公开号 EP2350111EP2350111 · 2011
  2. PROCESSES AND INTERMEDIATES FOR THE PRODUCTION OF FULVESTRANT
    ETTEMA GERRIT JAN BOUKE, GIELING REINERUS GERARDUS · 公开号 WO2010043404WO2010043404 · 2010
  3. FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF
    HU RENLE, WANG JIUCHENG, JIAO YAQI, LIANG HUA, et al. · 公开号 EP2417975EP2417975 · 2012
  4. FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF
    HU RENLE, WANG JIUCHENG, JIAO YAQI, LIANG HUA, et al. · 公开号 US2011318420US2011318420 · 2011
  5. FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF
    HU RENLE, WANG JIUCHENG, JIAO YAQI, LIANG HUA, et al. · 公开号 WO2011022861WO2011022861 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

氟维司群 杂质谱研究要点Fulvestrant — impurity profiling notes

下面这些是拿到 氟维司群 的 41 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 41 impurity entries for Fulvestrant, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances